Register now to attend the spring 2017 Innovation Fund finals

Wednesday, May 31 | 11:30 a.m. – 5:00 p.m.

The Innovation Fund is a $20 million fund that invests in proof-of-concept and early business development work for viable new startups created by faculty and students. The funds have been donated by alumni, and all proceeds from successful exits will be invested back into the Innovation Fund to ensure it is an evergreen, permanent feature of the University’s entrepreneurial ecosystem. During the Finals, applicants from across the University, Argonne National Lab, Fermilab, and the Marine Biological Laboratory will compete for up to $1.5m ($250,000 per team) in proof-of-concept funding. Get a sneak peak at this fall’s finalists below. Previous Innovation Fund finalists have built exciting technologies across a wide range of industries and causes, including healthcare IT, social impact, high powered computing, & education technology.  Register to attend the spring Innovation Fund Finals.

Learn more about the Spring 2017 Innovation Fund Finalists:

AVnovum is developing a new class of antimicrobial peptides that maintains healthy fungal microbiomes by preventing virulence and infection.  AVnovum works through mechanisms that specifically target virulent but not health-promoting microbes. AVnovum is driven by a diverse team of research scientists and advisors with scientific, entrepreneurial, and business backgrounds, who are dedicated to improving patient outcomes in those with diabetes, immunodeficiencies, and immunosuppression.

ClostraBio is a preclinical stage biopharmaceutical company dedicated to ending the burden and anxiety of living with food allergies. ClostraBio leverages recent discoveries in the microbiome – the trillions of bacteria and other microbes living in and on people – to create new drugs that prevent allergic reactions to food. ClostraBio is led by a world-renowned team of researchers and business experts from the University of Chicago, and has been featured in premier scientific journals.

Eysa is a platform which uses nanotechnology for improved disease diagnoses. Esya’s breakthrough imaging technology scans live cells, simultaneously measuring key chemicals in specific regions, to rapidly distinguish whether cells are healthy or diseased. By applying it to regions called lysosomes in cells, they can diagnose a whole range of lysosomal disorders from a blood draw and dramatically speed up testing.

O2M Technologies is a preclinical stage medical device company developing novel magnetic resonance oxygen imaging instrumentation and methodologies for cancer radiation treatment targeting. The O2M team uses oxygen information to specifically attack radiation resistant cancer tissues and avoid unnecessary damage to other areas which reduces post-treatment complications and improves cancer treatment success. The O2M team is a mix of practicing oncologists and imaging professionals with expertise in cancer biology, instrumentation and software development.

Switched Source provides advanced hardware solutions to electrical utilities that make their operations more efficient and reliable, while increasing their capability to host more renewable energy on the grid. Switched Source is led by a team that has deep domain experience in the electricity and power electronics space.

Register online